
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Inter-individual variability in neural response to low doses of LSD
The current study demonstrates across three cognitive domains, that acute responses to low doses of LSD depend on the baseline state and provides some support for LSD induced neuroadaptations that sustain beyond treatment.
Greater subjective effects of a low dose of LSD in participants with depressed mood
These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.
Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
Trait mindfulness, specifically description and non-judging of inner experience, was increased, and neuroticism was decreased after 4 weeks of MD compared to baseline. The remaining personality traits remained unchanged. Using conventional medication and/or having comorbid diagnoses did not change the MD-induced effects on mindfulness and personality traits after 4 weeks. Conclusion: MD induced changes in otherwise stable traits. Future placebo-controlled studies are warranted to confirm whether these changes occur in a controlled setting.
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
These results establish a well-validated regimen for further experiments probing the effects of repeated low doses of psilocybin. Results further substantiate anecdotal reports of the benefits of psilocybin microdosing as a therapeutic intervention, while pointing to a possible physiological mechanism.
Heart risks, serotonin, and fen-phen: 5 questions for 5-HT receptor researcher Bryan Roth
All those (phase 3) studies have one or two doses of psilocybin. If I were a betting man, I would say there’s little chance that that type of dosing would be an issue, but we still need to do clinical trials. The big concern is with repeated dosing, and lots of people are doing that now with microdosing. That’s extraordinarily risky until the appropriate studies have been done.
Review of studies on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or Psilocybin ...
The purpose of this paper is to present a review of studies (double-blind, longitudinal, open, randomized and controlled trials [mostly with placebo]) on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or psilocybin.
Unlocking the self: Can microdosing psychedelics make one feel more authentic?
We propose that feeling and behaving authentically could have a central role in explaining the positive effects of microdosing on health and wellbeing that are reported by current research.
Acute mood-elevating properties of microdosed LSD in healthy volunteers: a home-administered randomised controlled trial
Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness
Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
To conclude, the present study provides the first evidence that MD may have therapeutic value in adults diagnosed with ADHD or experiencing severe ADHD complaints.
Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial
These results suggest that microdosers may need to periodically suspend their microdosing routine to avoid tolerance.
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 – 2021) and recommendations for the field
We review data related to expectation and placebo effects, but argue that claims that microdosing effects are largely due to expectancy are premature and possibly wrong.
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose–response study
Low doses of LSD are safe, but produce negligible changes in mood or cognition in healthy volunteers.
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 – 2021)
We review data related to expectation and placebo effects, but argue that claims that microdosing effects are largely due to expectancy are premature and possibly wrong.
Microdosing of psychoactive substances in business practice
Abusing psychoactive substances has been a popular sport in the business world since the mid-19th century.
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Our results indicate health and wellness motives and perceived mental health benefits among microdosers
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing